The Short Form-36: Pre- Versus Post-Surgical Administration in Cardiac Surgery Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2008 by Weill Medical College of Cornell University.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Weill Medical College of Cornell University
ClinicalTrials.gov Identifier:
NCT00226265
First received: September 14, 2005
Last updated: March 31, 2008
Last verified: March 2008
  Purpose

The purpose of this study is to determine whether the SF-36 can be administered reliably to cardiac surgery patients (two to three days) post-surgery, with the patient answering the questions of this survey from a pre-surgical perspective.


Condition
Coronary Artery Bypass Grafting
Heart Diseases
Heart Valve Diseases

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: The Short Form-36: Pre-vs. Post-Surgical Administration in Cardiac Surgery Patients

Resource links provided by NLM:


Further study details as provided by Weill Medical College of Cornell University:

Estimated Enrollment: 200
Study Start Date: January 2000
Estimated Study Completion Date: September 2007
Detailed Description:

The purpose of this study, is to determine whether the SF-36 can be administered reliably to cardiac surgery patients (two to three days) post-surgery, with the patient answering the questions of this survey from a pre-surgical perspective.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Cardiac Surgery Patients at New York Presbyterian Hospital-Weill Cornell Medical College

Criteria

Inclusion Criteria:

  • Cardiac surgery patients who are between the ages of 18 and 100
  • Are English speaking
  • Able to give consent
  • Undergoing cardiac surgery including (but not limited to):

    • Aortic valve replacement (AVR)
    • Mitral valve replacement (MVR)
    • Tricuspid valve replacement (TVR)
    • Coronary artery bypass graft (CABG).

Exclusion Criteria:

  • Non-cardiac surgery patients
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00226265

Locations
United States, New York
The New York Presbyterian Hospital-Weill Medical Center
New York, New York, United States, 10021
Sponsors and Collaborators
Weill Medical College of Cornell University
Investigators
Principal Investigator: Mary E Charlson, MD Weill Medical College of Cornell University
  More Information

No publications provided

Responsible Party: Mary E. Charlson, Weill Cornell Medical College
ClinicalTrials.gov Identifier: NCT00226265     History of Changes
Other Study ID Numbers: 1203-069
Study First Received: September 14, 2005
Last Updated: March 31, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by Weill Medical College of Cornell University:
Cardiac surgery patients
Quality of Life
Recall bias
Aortic valve replacement
Mitral valve replacement
Tricuspid valve replacement
Coronary artery bypass graft surgery

Additional relevant MeSH terms:
Heart Diseases
Heart Valve Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on October 19, 2014